{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:10:10Z","timestamp":1763554210959,"version":"3.45.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Vietnam National University HoChiMinh City","award":["C2024-44-16"],"award-info":[{"award-number":["C2024-44-16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-02003-0","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:06:25Z","timestamp":1758549985000},"page":"1622-1634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluation of hepatitis B screening in low- and middle-income countries: a systematic review"],"prefix":"10.1007","volume":"47","author":[{"given":"Ha Thi","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong Thi Lan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinh Viet","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh Hoang Chau","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyen Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2003_CR1","unstructured":"World Health Organization. Hepatitis B. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. September 21, 2024."},{"key":"2003_CR2","unstructured":"Chronic Disease Advocacy Foundation. HBV Data at a Glance. 2022. https:\/\/cdafound.org\/polaris-regions-compare\/. September 21, 2024."},{"key":"2003_CR3","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. 2016."},{"issue":"1","key":"2003_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12889-018-5261-8","volume":"18","author":"CM Wright","year":"2018","unstructured":"Wright CM, Boudar\u00e8ne L, Ha NT, et al. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries. BMC Public Health. 2018;18(1):373. https:\/\/doi.org\/10.1186\/s12889-018-5261-8.","journal-title":"BMC Public Health"},{"issue":"4","key":"2003_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/jvh.13649","volume":"29","author":"Z Lu","year":"2022","unstructured":"Lu Z, Zhou Y, Yan R, et al. Post-vaccination serologic testing of infants born to hepatitis B surface antigen-positive mothers is more cost-effective in Zhejiang Province, China: a Markov chain analysis. J Viral Hepat. 2022;29(4):280\u20138. https:\/\/doi.org\/10.1111\/jvh.13649.","journal-title":"J Viral Hepat"},{"key":"2003_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijid.2018.08.024","volume":"78","author":"Y Wang","year":"2019","unstructured":"Wang Y, Shi JF, Wang L, et al. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. Int J Infect Dis. 2019;78:130\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2018.08.024.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"2003_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12884-021-03612-z","volume":"21","author":"M Bierhoff","year":"2021","unstructured":"Bierhoff M, Angkurawaranon C, Rijken MJ, et al. Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Pregnancy Childbirth. 2021;21(1):157. https:\/\/doi.org\/10.1186\/s12884-021-03612-z.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"5","key":"2003_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/ije\/dyy077","volume":"47","author":"F Cui","year":"2018","unstructured":"Cui F, Woodring J, Chan P, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. Int J Epidemiol. 2018;47(5):1529\u201337. https:\/\/doi.org\/10.1093\/ije\/dyy077.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2003_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/s12889-019-7095-4","volume":"19","author":"J Mokaya","year":"2019","unstructured":"Mokaya J, Burn EAO, Tamandjou CR, et al. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health. 2019;19(1):829. https:\/\/doi.org\/10.1186\/s12889-019-7095-4.","journal-title":"BMC Public Health"},{"issue":"23","key":"2003_CR10","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.vaccine.2021.04.041","volume":"39","author":"CR Tamandjou Tchuem","year":"2021","unstructured":"Tamandjou Tchuem CR, Andersson MI, Wiysonge CS, et al. Prevention of hepatitis B mother-to-child transmission in Namibia: a cost-effectiveness analysis. Vaccine. 2021;39(23):3141\u201351. https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.041.","journal-title":"Vaccine"},{"issue":"7","key":"2003_CR11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/21645515.2016.1141845","volume":"12","author":"YS Chen","year":"2016","unstructured":"Chen YS, Zheng H, Liu YM, et al. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. Hum Vaccin Immunother. 2016;12(7):1838\u201346. https:\/\/doi.org\/10.1080\/21645515.2016.1141845.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2003_CR12","first-page":"103","volume":"83","author":"F Guidozzi","year":"1993","unstructured":"Guidozzi F, Schoub BD, Johnson S, et al. Should pregnant urban south African women be screened for hepatitis B? S Afr Med J. 1993;83(2):103\u20135.","journal-title":"S Afr Med J"},{"issue":"4 Suppl 2","key":"2003_CR13","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/ije\/18.supplement_2.s38","volume":"18","author":"MA Lansang","year":"1989","unstructured":"Lansang MA, Domingo E, Lingao A, et al. A cost-effectiveness analysis of a simple micromethod for hepatitis B screening in hepatitis B virus control programmes. Int J Epidemiol. 1989;18(4 Suppl 2):S38-43. https:\/\/doi.org\/10.1093\/ije\/18.supplement_2.s38.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2003_CR14","first-page":"693","volume":"36","author":"T Vimolket","year":"2005","unstructured":"Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public Health. 2005;36(3):693\u20139.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2003_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2003_CR16","unstructured":"World Bank. World Bank Country and Lending Groups. 2024. https:\/\/datacatalogfiles.worldbank.org\/ddh-published\/0037712\/DR0090754\/OGHIST.xlsx. August 9, 2024."},{"key":"2003_CR17","unstructured":"World Health Organization. The world health report 2002: reducing risks, promoting healthy life. World Health Organization; 2002. June 21, 2025."},{"key":"2003_CR18","unstructured":"World Bank. Inflation, consumer prices (annual %). 2024. https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL.ZG. August 9, 2024."},{"key":"2003_CR19","unstructured":"World Bank. Official exchange rate (LCU per US$, period average). 2024. https:\/\/data.worldbank.org\/indicator\/PA.NUS.FCRF. August 9, 2024."},{"issue":"1","key":"2003_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Health"},{"issue":"2","key":"2003_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/S0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21(2):240\u20135.","journal-title":"Int J Technol Assess Health Care"},{"key":"2003_CR22","unstructured":"Maastricht University. Consensus Health Economic Criteria\u2014CHEC list. https:\/\/www.maastrichtuniversity.nl\/research\/caphri\/our-research\/creating-value-based-health-care\/chec-list-consensus-health-economic. September 29, 2024."},{"key":"2003_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4172\/2155-6156.1000438","volume":"5","author":"I Odnoletkova","year":"2014","unstructured":"Odnoletkova I, Goderis G, Pil L. Cost-effectiveness of therapeutic education to prevent the development and progression of type 2 diabetes: systematic review. J Diabetes Metab. 2014;5:438.","journal-title":"J Diabetes Metab"},{"issue":"3","key":"2003_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s44197-023-00132-1","volume":"13","author":"X Wang","year":"2023","unstructured":"Wang X, Du Z, Wang Y, et al. Impact and cost-effectiveness of biomedical interventions on adult hepatitis B elimination in China: a mathematical modelling study. J Epidemiol Glob Health. 2023;13(3):517\u201327. https:\/\/doi.org\/10.1007\/s44197-023-00132-1.","journal-title":"J Epidemiol Glob Health"},{"issue":"5","key":"2003_CR25","first-page":"216","volume":"7","author":"R Aggarwal","year":"1994","unstructured":"Aggarwal R, Naik SR. Prevention of hepatitis B infection: the appropriate strategy for India. Natl Med J India. 1994;7(5):216\u201320.","journal-title":"Natl Med J India"},{"key":"2003_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2334-4-31","volume":"4","author":"P Adibi","year":"2004","unstructured":"Adibi P, Rezailashkajani M, Roshandel D, et al. An economic analysis of premarriage prevention of hepatitis B transmission in Iran. BMC Infect Dis. 2004;4:31. https:\/\/doi.org\/10.1186\/1471-2334-4-31.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2003_CR27","first-page":"16","volume":"23","author":"M Sahni","year":"2004","unstructured":"Sahni M, Jindal K, Abraham N, et al. Hepatitis B immunization: cost calculation in a community-based study in India. Indian J Gastroenterol. 2004;23(1):16\u20138.","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"2003_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.tmaid.2009.04.001","volume":"7","author":"V Wiwanitkit","year":"2009","unstructured":"Wiwanitkit V. Cost concern on hepatitis B virus screening for workers pursuing work aboard. Travel Med Infect Dis. 2009;7(5):327. https:\/\/doi.org\/10.1016\/j.tmaid.2009.04.001.","journal-title":"Travel Med Infect Dis"},{"issue":"48","key":"2003_CR29","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1016\/j.vaccine.2015.09.011","volume":"33","author":"H Zheng","year":"2015","unstructured":"Zheng H, Wang FZ, Zhang GM, et al. An economic analysis of adult hepatitis B vaccination in China. Vaccine. 2015;33(48):6831\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.011.","journal-title":"Vaccine"},{"issue":"11","key":"2003_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165879","volume":"11","author":"D Lee","year":"2016","unstructured":"Lee D, Park SM. Cost-effectiveness analysis of hepatitis B vaccination strategies to prevent perinatal transmission in North Korea: selective vaccination vs. universal vaccination. PLoS ONE. 2016;11(11):e0165879. https:\/\/doi.org\/10.1371\/journal.pone.0165879.","journal-title":"PLoS ONE"},{"issue":"8","key":"2003_CR31","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2214-109X(16)30101-2","volume":"4","author":"S Nayagam","year":"2016","unstructured":"Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568\u201378. https:\/\/doi.org\/10.1016\/S2214-109X(16)30101-2.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2003_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12879-017-2660-x","volume":"17","author":"A Devine","year":"2017","unstructured":"Devine A, Harvey R, Min AM, et al. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Infect Dis. 2017;17(1):552. https:\/\/doi.org\/10.1186\/s12879-017-2660-x.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"2003_CR33","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jval.2020.06.015","volume":"23","author":"D Tordrup","year":"2020","unstructured":"Tordrup D, Hutin Y, Stenberg K, et al. Cost-effectiveness of testing and treatment for Hepatitis B virus and Hepatitis C virus infections: an analysis by scenarios, regions, and income. Value Health. 2020;23(12):1552\u201360. https:\/\/doi.org\/10.1016\/j.jval.2020.06.015.","journal-title":"Value Health"},{"key":"2003_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100264","volume":"19","author":"W Jing","year":"2020","unstructured":"Jing W, Liu J, Wu Y, et al. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: a decision-analytic Markov model. EClinicalMedicine. 2020;19:100264. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100264.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2003_CR35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/21645515.2019.1688031","volume":"16","author":"Y Zeng","year":"2020","unstructured":"Zeng Y, Luo M, Lin J, et al. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China. Hum Vaccin Immunother. 2020;16(4):955\u201364. https:\/\/doi.org\/10.1080\/21645515.2019.1688031.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2003_CR36","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/s2214-109x(21)00517-9","volume":"10","author":"S Su","year":"2022","unstructured":"Su S, Wong WC, Zou Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health. 2022;10(2):e278\u201387. https:\/\/doi.org\/10.1016\/s2214-109x(21)00517-9.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"2003_CR37","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.34172\/ijhpm.2021.126","volume":"11","author":"X Xu","year":"2022","unstructured":"Xu X, Wu C, Jiang L, et al. Cost-effectiveness of hepatitis B mass screening and management in high-prevalent rural China: a model study from 2020 to 2049. Int J Health Policy Manag. 2022;11(10):2115\u201323. https:\/\/doi.org\/10.34172\/ijhpm.2021.126.","journal-title":"Int J Health Policy Manag"},{"key":"2003_CR38","unstructured":"World Health Organization. Hepatitis in China. 2024. https:\/\/www.who.int\/china\/health-topics\/hepatitis. 08 June 2024."},{"issue":"1","key":"2003_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14218\/jcth.2013.00030","volume":"2","author":"YP Yan","year":"2014","unstructured":"Yan YP, Su HX, Ji ZH, et al. Epidemiology of hepatitis B virus infection in china: current status and challenges. J Clin Transl Hepatol. 2014;2(1):15\u201322. https:\/\/doi.org\/10.14218\/jcth.2013.00030.","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"2003_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145022","volume":"10","author":"C Geue","year":"2015","unstructured":"Geue C, Wu O, Xin Y, et al. Cost-effectiveness of HBV and HCV screening strategies\u2013a systematic review of existing modelling techniques. PLoS ONE. 2015;10(12):e0145022. https:\/\/doi.org\/10.1371\/journal.pone.0145022.","journal-title":"PLoS ONE"},{"key":"2003_CR41","unstructured":"World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis 2003."},{"issue":"1","key":"2003_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2334-13-181","volume":"13","author":"SJ Hahn\u00e9","year":"2013","unstructured":"Hahn\u00e9 SJ, Veldhuijzen IK, Wiessing L, et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13(1):181. https:\/\/doi.org\/10.1186\/1471-2334-13-181.","journal-title":"BMC Infect Dis"},{"key":"2003_CR43","unstructured":"World Health Organization. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15. World Health Organization;2015."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02003-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:08:16Z","timestamp":1763554096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02003-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02003-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}